Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Position Lowered by Brown Advisory Inc.

Brown Advisory Inc. lessened its position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 7.9% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 211,405 shares of the company’s stock after selling 18,100 shares during the quarter. Brown Advisory Inc. owned approximately 0.15% of Xeris Biopharma worth $497,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Alpine Global Management LLC lifted its position in Xeris Biopharma by 33.3% in the 3rd quarter. Alpine Global Management LLC now owns 300,000 shares of the company’s stock worth $558,000 after buying an additional 75,000 shares in the last quarter. Barclays PLC lifted its position in Xeris Biopharma by 14.1% in the 3rd quarter. Barclays PLC now owns 105,743 shares of the company’s stock worth $197,000 after buying an additional 13,040 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in Xeris Biopharma by 351.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 15,973 shares of the company’s stock worth $38,000 after buying an additional 12,432 shares in the last quarter. SG Americas Securities LLC lifted its position in Xeris Biopharma by 83.9% in the 4th quarter. SG Americas Securities LLC now owns 33,777 shares of the company’s stock worth $79,000 after buying an additional 15,414 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. purchased a new stake in Xeris Biopharma in the 3rd quarter worth approximately $66,000. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Stock Performance

Shares of XERS opened at $1.93 on Monday. The company’s fifty day moving average is $1.95 and its 200-day moving average is $2.22. Xeris Biopharma Holdings, Inc. has a 12 month low of $1.46 and a 12 month high of $3.26. The company has a debt-to-equity ratio of 49.27, a quick ratio of 1.81 and a current ratio of 2.37.

Xeris Biopharma (NASDAQ:XERS) last posted its earnings results on Thursday, May 9th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). Xeris Biopharma had a negative net margin of 37.58% and a negative return on equity of 16,662.63%. The firm had revenue of $40.64 million during the quarter, compared to analyst estimates of $41.56 million. Analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on XERS. Oppenheimer began coverage on shares of Xeris Biopharma in a research report on Thursday, March 28th. They issued an “outperform” rating and a $5.00 target price for the company. HC Wainwright increased their price target on shares of Xeris Biopharma from $5.50 to $6.00 and gave the stock a “buy” rating in a research note on Thursday, March 7th. Finally, Piper Sandler restated an “overweight” rating and set a $3.00 price target (down previously from $4.00) on shares of Xeris Biopharma in a research note on Friday, May 10th.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.